PharmiWeb.com - Global Pharma News & Resources
17-Jul-2019

CO.DON AG: Negotiations with Xintela on joint venture discontinued

CO.DON AG / Key word(s): Strategic Company Decision
CO.DON AG: Negotiations with Xintela on joint venture discontinued

17-Jul-2019 / 10:28 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


CO.DON AG (ISIN: DE DE000A1K0227)

CO.DON: Negotiations with Xintela on joint venture discontinued

Berlin / Teltow, 17.07.2019 - The negotiations announced on 9 July 2018 with Xintela A.B. regarding the establishment of a joint venture with the aim of developing a stem cell product for the treatment of osteoarthritis are being discontinued.

After careful analysis, the Management Board of CO.DON AG has concluded today that that there is no longer any potential for an agreement to establish a joint venture with Xintela A.B. As a result of the open and constructive discussions, it has now become clear that the assessment of the contribution to be made to the joint venture by the respective parties is too different.

Contact:
Matthias Mei├čner, M.A.
Director Investor Relations / Public Relations
Tel. +49 (0)30-240352330
Fax +49 (0)30-240352309
E-Mail: ir@codon.de


17-Jul-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CO.DON AG
Warthestra├če 21
14513 Teltow
Germany
Phone: 03328 43460
Fax: 03328 434643
E-mail: info@codon.de
Internet: www.codon.de
ISIN: DE000A1K0227
WKN: A1K022
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 842463

 
End of Announcement DGAP News Service

Editor Details

Last Updated: 17-Jul-2019